ANTIBODIES FOR PREVENTION AND THERAPY: Edited by John R. Mascola and Richard A. KoupMonoclonal antibodies to host cellular receptors for the treatment and prevention of HIV-1 infectionPace, Craiga,b; Markowitz, MartinbAuthor Information aGilead Sciences, Foster City, California bAaron Diamond AIDS Research Center, New York City, New York, USA Correspondence to Martin Markowitz, MD, Aaron Diamond AIDS Research Center, 455 First Avenue, 7th Floor, New York, NY 10016, USA. Tel: +1 212 448 5020; e-mail: [email protected] Current Opinion in HIV and AIDS: May 2015 - Volume 10 - Issue 3 - p 144-150 doi: 10.1097/COH.0000000000000146 Buy Metrics Abstract Purpose of review Clinically relevant monoclonal antibodies (mAb) to host cellular receptors have been generated to both the CD4 receptor and the CCR5 coreceptor, cell surface proteins critical for HIV-1 entry. Ibalizumab is a novel humanized mAb that binds to a conformational epitope on CD4 and blocks entry of HIV-1. It has broad and potent antiviral activity in vitro and in vivo. PRO 140 is a humanized mAb that binds to the CCR5 coreceptor and inhibits CCR5-tropic HIV-1 by interfering with viral entry. Antiviral activity has been demonstrated both in vitro against R5 viruses and in vivo in HIV-1-infected individuals harboring CCR5-tropic virus. Recent findings Both antibodies have been administered intravenously in early-phase clinical trials, and current emphasis is on the development of formulations that can be administered subcutaneously. Most recently, bispecific antibodies combining either ibalizumab or PRO 140 with anti-Env broadly neutralizing antibodies have been constructed with vastly improved in-vitro neutralizing profiles, and may offer substantial advantages in the clinic. Summary mAb to host cellular receptors particularly when combined with broadly neutralizing antibodies in novel conformations may offer advances in both the treatment and prevention of HIV-1 infection. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.